Pharmaceutical Product Monograph: Ceftazidime Sodium (1 g, 2 g)
In the pharmaceutical industry, Ceftazidime is a parenteral, semi-synthetic Third-Generation Cephalosporin antibiotic. As a pharmacist and manufacturer, I view this molecule as the “Anti-Pseudomonal Specialist”—it is technically designed with a complex side chain that gives it superior activity against Pseudomonas aeruginosa compared to almost any other cephalosporin.
At your WHO-GMP facility in Mumbai, Ceftazidime is a critical “Institutional SKU” for ICU and Critical Care portfolios. It is the primary weapon for hospital-acquired infections where Gram-negative “Superbugs” are suspected.
Therapeutic Profile: Primary Indications
Ceftazidime is indicated for severe infections where Gram-negative bacteria, particularly Pseudomonas, are the likely cause.
| Indication | Clinical Context | Technical Rationale |
| Hospital-Acquired Pneumonia | VAP / HAP | Gold Standard: Effectively targets Pseudomonas and Klebsiella in ventilator-dependent patients. |
| Febrile Neutropenia | Oncology / Hematology | Often used as monotherapy to treat unexplained fever in cancer patients with low white cell counts. |
| Bacterial Meningitis | CNS Infection | Excellent CSF penetration (when meninges are inflamed), specifically for Gram-negative meningitis. |
| Complicated UTI | Pyelonephritis / Sepsis | Used for severe kidney infections or post-urological surgery complications. |
| Cystic Fibrosis | Respiratory Crisis | Used for the management of recurrent pulmonary infections in CF patients. |
| Septicemia | Bloodstream Infection | Used as empirical therapy for patients in septic shock. |
Mechanism: Cell Wall Transpeptidase Inhibition
Ceftazidime works by sabotaging the structural integrity of the bacterial “outer shell”:
PBP High Affinity: The drug enters the bacterial cell and binds with high affinity to Penicillin-Binding Proteins (PBPs), specifically PBP-3.
Peptidoglycan Blockade: It inhibits the final cross-linking (transpeptidation) step of cell wall synthesis.
Filamentation & Lysis: Technically, this leads to the formation of long, unstable bacterial filaments that cannot divide and eventually undergo osmotic lysis (the cell bursts).
The Pharmacist’s “Technical Warning”
The “Pseudomonas” Paradox: As a pharmacist, I must emphasize that while Ceftazidime is an elite Gram-negative killer, it has very poor activity against Gram-positive bacteria like Staph. aureus (MSSA/MRSA). It should not be used as monotherapy if a “Staph” infection is suspected.
Renal Adjustment: Ceftazidime is excreted almost entirely unchanged by the kidneys. For patients with a $GFR < 50 \text{ mL/min}$, the dose must be reduced to prevent neurotoxicity (confusion, tremors).
The “L-Arginine” Note: Many formulations (including yours in Mumbai) use L-Arginine to stabilize the pH. This is technically safer than Sodium Carbonate as it prevents the release of excessive $CO_2$ gas during reconstitution.
Incompatibility: Never mix Ceftazidime and Aminoglycosides (like Amikacin or Gentamicin) in the same IV bag; they will physically precipitate and neutralize each other.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Aseptic Powder” USP: On your digital marketplace, highlight your Sterile Crystallization and Aseptic Filling. Ceftazidime is highly sensitive; ensuring zero moisture in the vial is the technical key to maintaining a 24-month shelf life.
The “Oncology Tendon” Advantage: Market Ceftazidime specifically to International Cancer Centers. Its status as a preferred agent for neutropenic sepsis makes it a high-volume, recurring revenue SKU for oncology procurement.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Ceftazidime 1 g and 2 g vials to support your registration in international B2B tenders for hospital and critical care.